Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.31
-0.01 (-0.07%)
Nov 6, 2025, 4:00 PM EST - Market closed
DMAA Statistics
Total Valuation
DMAA has a market cap or net worth of $345.65 million. The enterprise value is $346.22 million.
| Market Cap | 345.65M |
| Enterprise Value | 346.22M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DMAA has 33.52 million shares outstanding.
| Current Share Class | 33.52M |
| Shares Outstanding | 33.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +31.40% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 47.31% |
| Float | 23.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 195.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 53.19 |
| Average Volume (20 Days) | 34,446 |
Short Selling Information
The latest short interest is 51,840, so 0.15% of the outstanding shares have been sold short.
| Short Interest | 51,840 |
| Short Previous Month | 50,181 |
| Short % of Shares Out | 0.15% |
| Short % of Float | 0.22% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -479,734 |
| Pretax Income | -479,734 |
| Net Income | -479,734 |
| EBITDA | n/a |
| EBIT | -479,734 |
| Earnings Per Share (EPS) | -$0.06 |
Balance Sheet
The company has $1,351 in cash and $662,324 in debt, giving a net cash position of -$660,973 or -$0.02 per share.
| Cash & Cash Equivalents | 1,351 |
| Total Debt | 662,324 |
| Net Cash | -660,973 |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | -244,845 |
| Book Value Per Share | -0.03 |
| Working Capital | -790,678 |
Cash Flow
| Operating Cash Flow | -295,311 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.14% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |